This course covers the regulatory framework governing artificial intelligence and machine learning in pharmaceutical GMP

manufacturing from the FDA FRAME Initiative through to the Purolea warning letter, the ISPE GAMP AI Guide and FDA's

planned 2026 AI/ML Quality Considerations guidance.

The course opens with FDA's unambiguous regulatory position. Existing CGMP regulations apply fully to AI systems in pharmaceutical manufacturing now. There is no AI-specific exemption. 21 CFR 211.68 requires that electronic equipment used in manufacturing be validated for its intended use an AI model used in a quality or manufacturing decision is electronic equipment under 211.68. The CSA final guidance (September 2025) explicitly includes AI and machine learning

systems within scope.

The FDA regulatory timeline is covered in full from the CDER FRAME Initiative in 2021, the landmark AI in Drug Manufacturing discussion paper in March 2023, the January 2025 draft guidance on AI to support regulatory decision-making, the joint FDA and EMA Guiding Principles of Good AI Practice published January 2026 and the planned 2026 AI/ML Quality Considerations in Pharmaceutical Manufacturing guidance on FDA's formal guidance agenda.

The April 2026 Purolea Pharmaceuticals warning letter is examined in depth the first FDA enforcement action citing AI misuse in pharmaceutical manufacturing. Three specific findings are covered: AI-generated batch records accepted without human verification, AI-generated SOPs contradicting validated process parameters, and absence of AI system validation under 21 CFR 211.68. The course explains why the absence of validation was the foundational failure that enabled the other two findings.

The four AI application categories in pharmaceutical manufacturing are covered process monitoring and control, predictive maintenance, environmental monitoring and contamination detection, and quality system and document management with their respective risk profiles and validation expectations.

AI validation under CSA principles is covered in three steps intended use assessment driving the scope of assurance activities, risk-based assurance planning including scripted versus unscripted testing, and lifecycle and change control requirements including model drift monitoring, vendor-pushed update assessment and training data integrity.

The ISPE GAMP AI Guide (July 2025) four-category framework is covered in depth informative AI, assistive AI, autonomous AI and independent AI including the critical controls for each category and how generative AI used in CGMP documentation falls into the highest risk category regardless of human approval of the output.

The course concludes with five immediate actions every site should take before the 2026 guidance is finalised and the warning signs FDA inspectors are increasingly alert to in AI governance programmes.

Suitable for: QA managers and specialists, validation engineers and scientists, IT teams managing GxP systems, laboratory systems administrators, manufacturing operations managers and all personnel whose roles involve implementing, reviewing or approving AI or machine learning tools in any GxP-regulated activity.

Approx. 30 minutes | 5 assessment questions | Certificate on completion

Sources: 21 CFR 211.68 | CSA Final Guidance September 2025 | FDA FRAME Initiative | FDA AI Discussion Paper March 2023 |

FDA Draft Guidance January 2025 | ISPE GAMP AI Guide July 2025 | Purolea Warning Letter April 2026 | fda.gov